ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

benserazide, levodopa drug combination

Also written as “HRG2010 Capsule, Sinemet®, Madopar®”, “Madopar® 250” and “levodopa/benserazide”.

Its studies are mostly in Parkinson Disease, led by 2 companies.

Furthest: phase 1, since Jan 24, 20123 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bial - Portela C20 open or runningphase 1since Jan 24, 2012Jan 24, 2012none ahead
Jiangsu HengRui Medicineits history only10 open or runningphase 1since May 9, 2025May 9, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bial - Portela C only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 24, 2012First study: phase 1 study in Parkinson DiseaseFirst studyNCT01533116 · 52 enrolled · Canada
  2. Mar 27, 2017Phase 1 study in Parkinson DiseaseNCT03097211 · 38 enrolled · Portugal

TargetBeta

DDC →read by rule
“An orally available combination of benserazide, an aromatic L-amino acid decarboxylase (AADC) inhibitor, and levodopa, an inert, metabolic precursor to dopamine, with dopaminergic and antiparkinsonian properties”NCIt, by rule

Other programs on DDC

ProgramCompanyFurthest phaseStudies
CarbidoparuleNovartisphase 425

Studies

All 2 Bial - Portela C leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03097211Parkinson Disease · Portugal1CompletedOct 20, 200638
NCT01533116Parkinson Disease · Canada1CompletedAug 200952

How it is read

Names in the registry

  • “HRG2010 Capsule, Sinemet®, Madopar®”, 1 entry
  • “Madopar® 250”, 1 entry
  • “levodopa/benserazide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.